

Cereno Scientific to Present New Data of CS014 at the Pharmacology 2025 on December 15-18

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will present new data of CS014 at the scientific conference Pharmacology 2025 organized by the British Pharmacology Society on December 16-18 in Belfast, Northern Ireland. The findings relate to CS014's preclinical studies and Phase I trial, supporting advancement of the program into Phase II development.

CS014 is being developed as a next-generation HDAC inhibitor and novel chemical entity designed to modulate epigenetic pathways that target the root cause of cardiovascular and pulmonary diseases. Non-clinical studies have demonstrated potent effects on pathways involved in vascular remodeling and fibrosis, which are key drivers of disease progression in several cardiovascular and pulmonary conditions. The recently completed Phase I study confirmed that CS014 has a favorable safety profile and is well tolerated at and above exposure levels that, based on non-clinical data, are predicted to support maximal effects on the reversal of pulmonary vascular remodeling and fibrosis. These findings support advancement of CS014 into Phase II clinical development with an initial focus on idiopathic pulmonary fibrosis (IPF).

"Sharing our CS014 data at Pharmacology 2025 is an important milestone for our HDAC inhibitor platform and marks the first scientific presentation from this program. It reflects the steady progress we are making across our pipeline as we prepare CS014 for the next clinical stage. We look forward to continuing this momentum as we advance our mission to pioneer treatments that enhance and extend life for people with rare cardiovascular and pulmonary diseases," said Sten R. Sørensen, CEO of Cereno Scientific.

Oral presentation: Safety, tolerability, and pharmacokinetics (PK) of the novel HDAC inhibitor CS014: a first-in-human (FIH) trial

Authors: Tatiane Abreu Dall'Agnol, Fredrik Frick, Rahul Agrawal, Björn Dahlöf, Johan Nilsson, Johan Bylund, Erik Westrin, Nicholas Oakes
Presenting author: Tatiane Abreu Dall'Agnol
Paper Number: 256

Poster presentation: CS014, a novel precision deuterated valproic acid, reverses vascular remodeling in a preclinical model of pulmonary artery hypertension (PAH)

Authors: Tatiane Abreu Dall'Agnol, Fredrik Frick, Rahul Agrawal, Björn Dahlöf, Nicholas Oakes
Presenting author: Nicholas Oakes
Paper Number: 258

More information about the scientific conference is available on:

<https://www.miceconciergeme.com/pharmacology2025>

The scientific poster and presentation will be available on Cereno Scientific's webpage after the conference conclusion.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email: tove.bergenholt@cerenoscientific.com

Phone: +46 73- 236 62 46

About CS014

CS014 is a proprietary new chemical entity and a HDAC inhibitor. Being an epigenetic modulator, with a multimodal mechanism of action, CS014 has the potential to target the underlying pathophysiology of several rare cardiovascular and pulmonary diseases with high unmet medical needs. The initial target is idiopathic pulmonary fibrosis (IPF). In non-clinical studies, CS014 has demonstrated strong effects on vascular remodeling and fibrosis, suggesting disease-modifying potential. The findings from the Phase I trial will inform the next steps in advancing CS014 as a potential new treatment for patients with severe, progressive diseases that currently lack effective therapies. Preparations and studies are underway to support the transition to a Phase II trial of CS014.

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and pulmonary hypertension.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.

Press release
December 3, 2025

Cereno Scientific